Novo Nordisk ties up with Metaphore to develop new obesity drugs
Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation
Omega collaboration will leverage the company™s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Cellarity to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cellarity Named a Top Place to Work for 2023 by The Boston Globe
Cellarity Announces Partnership with Chan Zuckerberg Initiative to Advance New Machine Learning Algorithms for Single-Cell Analysis
Cellarity Recognized as a 2023 Prix Galien USA Nominee for Best Startup
SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem.
Cellarity Strengthens Executive Leadership Team
Flagship-founded Cellarity has hauled in $121 million in new series C funds as the biotech continues to push its cell behavior therapies toward the clinic.